The predictive value of plasma cystatin C for acute coronary syndrome treated with percutaneous coronary intervention

Heart and Lung: Journal of Acute and Critical Care

Volumn 41, Issue 5, 2012, Pages 456-462

  Sun, Tong Wen ^a   Xu, Qing Yan ^a   Yao, Hai Mu ^a   Zhang, Xiao Juan ^a   Wu, Qiong ^a   Zhang, Jin Ying ^a   Li, Ling ^a   Zhang, Yan Zhou ^a   Kan, Quan Cheng ^a   Guan, Fang Xia ^b   Wang, Le Xin ^c  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^b Academy of Medical Science   (China)

^c CHARLES STURT UNIVERSITY   (Australia)

Author keywords

Acute coronary syndrome; Cystatin C; Major adverse cardiac events; Percutaneous coronary intervention; Prognosis

Indexed keywords

CREATININE; CYSTATIN C;

ACUTE CORONARY SYNDROME; ADULT; ANGINA PECTORIS; ARTICLE; CARDIOVASCULAR MORTALITY; CORONARY ARTERY RECANALIZATION; CREATININE BLOOD LEVEL; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; INCIDENCE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PERCUTANEOUS CORONARY INTERVENTION; PREDICTIVE VALUE; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STROKE; SURVIVAL RATE;

ACUTE CORONARY SYNDROME; BIOLOGICAL MARKERS; CORONARY ANGIOGRAPHY; CYSTATIN C; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 84865599053     PISSN: 01479563     EISSN: 15273288     Source Type: Journal    
DOI: 10.1016/j.hrtlng.2012.04.007     Document Type: Article

References (30)

1. Brzin J., Popovic T., Turk V., Borchart U., Machleidt W. Human cystatin, a new protein inhibitor of cysteine proteinases. Biochem Biophys Res Commun 1984, 118:103-109.
2. Cheng X.W., Kuzuya M., Nakamura K., Di Q., Liu Z.X., Sasaki T., et al. Localization of cysteine protease, cathepsin S, to surface of vascular smooth muscle cells by association with integrin alphanubeta3. Am J Pathol 2006, 168:685-694.
3. Newman D.J. Cystatin C. Ann Clin Biochem 2002, 39:89-104.
4. Fliser D., Ritz E. Serum cystatin C concentration as a marker of renal dysfunction in the elderly. Am J Kidney Dis 2001, 37:79-83.
5. Levey A.S. Measurement of renal function in chronic renal disease. Kidney Int 1990, 38:167-184.
6. Coll E., Botey A., Alvarez L., Poch E., Quinto L., Saurina A., et al. Serum cystatin C as a new marker for noninvasive estimation of glomerular filtration rate and as a marker for early renal impairment. Am J Kidney Dis 2000, 36:29-34.
7. Dharnidharka V.R., Kwon C., Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis 2002, 40:221-226.
8. Levin A., Cystatin C. Serum creatinine, and estimates of kidney function: searching for better measures of kidney function and cardiovascular risk. Ann Intern Med 2005, 142:586-588.
9. Hoek F.J., Kemperman F.A., Krediet R.T. A comparison between cystatin C, plasma creatinine and the Cockcroft and Gault formula for the estimation of glomerular filtration rate. Nephrol Dial Transplant 2003, 18:2024-2031.
10. Risch L., Blumberg A., Huber A. Rapid and accurate assessment of glomerular filtration rate in patients with renal transplants using serum cystatin C. Nephrol Dial Transplant 1999, 14:1991-1996.
11. Ix J.H., Shlipak M.G., Chertow G.M., Whooley M.A. Association of cystatin C with mortality, cardiovascular events, and incident heart failure among persons with coronary heart disease: data from the Heart and Soul Study. Circulation 2007, 115:173-182.
12. Djousse L., Kurth T., Gaziano J.M. Cystatin C and risk of heart failure in the Physicians Health Study (PHS). Am Heart J 2008, 155:82-86.
13. Alehagen U., Dahlstrom U., Lindahl T.L. Cystatin C and NT-proBNP, a powerful combination of biomarkers for predicting cardiovascular mortality in elderly patients with heart failure: results from a 10-year study in primary care. Eur J Heart Fail 2009, 11:354-360.
14. Luc G., Bard J.M., Lesueur C., Arveiler D., Evans A., Amouyel P., et al. Plasma cystatin C and development of coronary heart disease: The PRIME Study. Atherosclerosis 2006, 185:375-380.
15. Shlipak M.G., Sarnak M.J., Katz R., Fried L.F., Seliger S.L., Newman A.B., et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med 2005, 352:2049-2060.
16. Ge C., Ren F., Lu S., Chen X., Wu X. Clinical prognostic significance of plasma cystatin C levels among patients with acute coronary syndrome. Clin Cardiol 2009, 32:644-648.
17. Jernberg T., Lindahl B., James S., Larsson A., Hansson L.O., Wallentin L. Cystatin C: a novel predictor of outcome in suspected or confirmed non-ST-elevation acute coronary syndrome. Circulation 2004, 110:2342-2348.
18. Taglieri N., Fernandez-Berges D.J., Koenig W., Consuegra-Sanchez L., Fernandez J.M., Robles N.R., et al. Plasma cystatin C for prediction of 1-year cardiac events in Mediterranean patients with non-ST elevation acute coronary syndrome. Atherosclerosis 2010, 209:300-305.
19. Ichimoto E., Jo K., Kobayashi Y., Inoue T., Nakamura Y., Kuroda N., et al. Prognostic significance of cystatin C in patients with ST-Elevation myocardial infarction. Circ J 2009, 73:1669-1673.
20. Shlipak M.G., Wassel Fyr C.L., Chertow G.M., Harris T.B., Kritchevsky S.B., Tylavsky F.A., et al. Cystatin C and mortality in the elderly: the health, aging, and body composition study. J Am Soc Nephrol 2006, 17:254-261.
21. Keller T., Messow C.M., Lubos E., Nicaud V., Wild P.S., Rupprecht H.J., et al. Cystatin C and cardiovascular mortality in patients with coronary artery disease and normal or mildly reduced kidney function: results from the Athero Gene study. Eur Heart J 2009, 30:314-320.
22. Koenig W., Twardella D., Brenner H., Rothenbacher D. Plasma concentrations of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events: more than simply a marker of glomerular filtration rate. Clin Chem 2005, 51:321-328.
23. Collet J.P., Montalescot G., Lison L., Choussat R., Anki A., Drobinski G., et al. Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris. Circulation 2001, 103:658-663.
24. Fischman D.L., Leon M.B., Baim D.S., Schatz R.A., Savage M.P., Penn I., et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med 1994, 331:496-501.
25. Park S.J. Inflammatory biomarkers for prediction of outcomes after unprotected left main coronary intervention. Circulation 2005, 112:2226-2227.
26. Chia S., Senatore F., Raffel O.C., Lee H., Wackers F.J., Jang I.K. Utility of cardiac biomarkers in predicting infarct size, left ventricular function, and clinical outcome after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. JACC Cardiovasc Interv 2008, 1:415-423.
27. Hamm C.W., Bassand J.P., Agewall S., Bax J., Boersma E., Bueno H., et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. The Task force on the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011, 32:2999-3054.
28. King S.B., Smith S.C., Hirshfeld J.W., Jacobs A.K., Morrison D.A., Williams D.O., et al. 2007 Focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Update for Percutaneous Coronary Intervention. Writing on Behalf of the 2005 Writing Committee. Circulation 2008, 117:261-295.
29. Blackman D.J., Pinto R., Ross J.R., Seidelin P.H., Ing D., Jackevicius C., et al. Impact of renal insufficiency on outcome after contemporary percutaneous coronary intervention. Am Heart J 2006, 151:146-152.
30. Zhang R.Y., Zhu Z.B., Zhang Q., Yang Z.K., Hu J., Lv A.K., et al. Impact of moderate or severe renal insufficiency on long-term outcomes in patients undergoing drug-eluting stent based coronary intervention. Int J Cardiol 2009, 136:72-79.